All In Biotech

Drug Trial Radar · NCT05432960

Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD)

International, Multi-Center, Double-blind, Randomized, Placebo-Controlled, Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD)

Last checked: Nov 20, 2026Latest source record: Nov 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

WithdrawnPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Withdrawn

Enrollment

0

Actual

Start

Dec 2023

Primary completion

Aug 2025

Study completion Aug 2025

Sponsor

Lead sponsor
R-Pharm International, LLCIndustry
Sponsor type
Industry
Collaborators
Exacte Labs LLC; Ministry of Health, Russian Federation; Scientific Center EFiS LLC; Data Management 365
First posted
Jun 27, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate the efficacy of RPH-104 when administered at a dose of 160 mg on Day 0, Day 7, Day 21 and then once every 2 weeks (Q2W) subcutaneous (SC) in patients with Adult Onset Still's Disease (AOSD). Furthermore, the study is scheduled to investigate pharmacokinetic (PK) and pharmacodynamic (PD) parameters of RPH-104.

Conditions

  • Adult-Onset Still's Disease
  • AOSD

Interventions

  • RPH-104Biological

    solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial

  • PlaceboDrug

    Normal Saline (0.9% Sodium Chloride solution)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time (number of days) to exacerbation during 24 weeks after randomization while taking RPH-104 vs placebo in patients with AOSDTime frame: from randomization (visit 16, week 29) to exacerbation, up to week 53

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Research Institute of Rheumatology. V.A. Nasonova

    Moscow, Russia

  • Clinic of Nephrology, Internal and Occupational Diseases. EAT. Tareeva, University Clinical Hospital No. 3

    Moscow, Russia

  • State Budgetary Institution of Healthcare Leningrad Regional Clinical Hospital, Department of Rheumatology

    Saint Petersburg, Russia

  • FGBU "National Medical Research Center named after V.A. Almazov", Ministry of Health of the Russian Federation, Department of Rheumatology

    Saint Petersburg, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.